Using disease-modifying therapies in sickle cell disease

Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):519-531. doi: 10.1182/hematology.2023000485.ABSTRACTAs curative therapy using allogeneic hematopoietic stem cell transplantation as well as gene therapy and gene editing remains inaccessible to most patients with sickle cell disease, the availability of drug therapies that are safe, efficacious, and affordable is highly desirable. Increasing progress is being made in developing drug therapies based on our understanding of disease pathophysiology. Four drugs, hydroxyurea, L-glutamine, crizanlizumab, and voxelotor, are currently approved by the US Food and Drug Administration, with multiple others at various stages of testing. With the limited efficacy of individual agents, combinations of agents will likely be required for optimal outcomes.PMID:38066905 | PMC:PMC10727073 | DOI:10.1182/hematology.2023000485
Source: Hematology ASH Education Program - Category: Hematology Authors: Source Type: research